A randomised, multicentre, double-blind, placebo-controlled, phase III study of first line Carboplatin and Paclitaxel in combination with Durvalumab, followed by maintenance durvalumab with or without Olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer [DUO-E]

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Lai, Li Hoon (Project Manager)

Project: Research

Project Details

Effective start/end date14/04/2131/12/24


  • Endometrial cancer
  • Medical oncology
  • Clinical trial